Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071529 | 1.00 | TAAR1 (0.47) | TAAR1HTR2AHRH1ADRB2ADRB1 | |
| Formic Acid SCHEMBL5073038 | 0.91 | ADRB2 (0.42) | TAAR1HTR2AHRH1ADRB2ADRB1 | |
| Formic Acid SCHEMBL5073674 | 0.91 | ADRB2 (0.42) | TAAR1HTR2AHRH1ADRB2ADRB1 | |
| SCHEMBL6320788 | 0.80 | ADRB2 (0.41) | TAAR1ADRB2ADRB1SLC6A4CYP2D6 | |
| SCHEMBL5076834 | 0.80 | ADRB2 (0.41) | TAAR1ADRB2ADRB1SLC6A4CYP2D6 | |
| SCHEMBL5071527 | 0.80 | ADRB2 (0.41) | TAAR1ADRB2ADRB1SLC6A4CYP2D6 | |
| SCHEMBL16545294 | 0.79 | SLC6A4 (0.49) | TAAR1HTR2AHRH1SLC6A4CYP2D6 | |
| SCHEMBL9284882 | 0.79 | ADRB2 (0.44) | ADRB2ADRB1SLC6A4CYP2D6NFKB1 | |
| SCHEMBL9232403 | 0.79 | ADRB2 (0.44) | ADRB2ADRB1SLC6A4CYP2D6NFKB1 | |
| SCHEMBL6222532 | 0.77 | NISCH (0.50) | TAAR1HRH1ADRB2ADRB1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | TAAR1 1785/4885HTR2A 3307/4885HRH1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.